Oramed Pharmaceuticals (NASDAQ:ORMP) reported quarterly losses of $(0.18) per share. This is a 5.88 percent decrease over losses of $(0.17) per share from the same period last year.
Bavarian Nordic Beefs Up Chikungunya Vaccine Race With Valneva With Encouraging Late-Stage Trial Data
Bavarian Nordic A/S's (OTC: BVNRY) phase 3 chikungunya virus vaccine (CHIKV VLP (PXVX0317) clinical trial has hit its primary endpoint in
